IRadimed Q2 profit rises on record monitor bookings

IRADIMED

31/07/2026 13:26

Overview
US MRI-compatible device maker's Q2 revenue rose 0.5% year-over-year to $20.5 mln
Q2 adjusted EPS was $0.46, while GAAP diluted EPS was $0.41
Company declared regular quarterly cash dividend and reaffirmed full-year 2026 guidance

Outlook
IRadimed expects Q3 revenue of $23.0 mln to $24.5 mln
Company sees Q3 GAAP diluted EPS of $0.49 to $0.54 and non-GAAP EPS of $0.54 to $0.59
IRadimed reaffirms 2026 revenue guidance of $91.0 mln to $96.0 mln and GAAP EPS of $1.90 to $2.05

Result Drivers
NEW PRODUCT LAUNCH - Co said Q2 marked the start of the 3870 MR IV pump launch and transition from the older 3860 model, with initial shipments meeting plan
RECORD MONITOR BOOKINGS - Co said domestic monitor unit bookings set a record in Q2
GROSS MARGIN PRESSURE - Co said gross margin declined due to expected startup challenges with the new 3870 pump ramp, but expects improvement as volumes increase

Company press release: ID:nGNXbBvKZf

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Slight Beat*
$20.5 mln
$20.35 mln (2 Analysts)
Q2 Adjusted EPS
Beat
$0.46
$0.42 (2 Analysts)
Q2 EPS
 
$0.41
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for IRadimed Corp is $118.00, about 23.9% above its July 30 closing price of $95.21
The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 45 three months ago

Reuters Recommended Reads
July 30 - Merit Medical Q2 adjusted EPS beats estimates, raises 2026 outlook
July 30 - Stryker Q2 adjusted EPS beats estimates, narrows 2026 outlook
July 30 - Baxter raises annual profit forecast on strength in drug compounding business

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)